Literature DB >> 14744254

Mixed-lineage kinases: a target for the prevention of neurodegeneration.

Leo H Wang1, Cagri G Besirli, Eugene M Johnson.   

Abstract

The activation of the c-Jun N-terminal kinase (JNK) pathway is critical for naturally occurring neuronal cell death during development and may be important for the pathological neuronal cell death of neurodegenerative diseases. The small molecule inhibitor of the mixed-lineage kinase (MLK) family of kinases, CEP-1347, inhibits the activation of the JNK pathway and, consequently, the cell death in many cell culture and animal models of neuronal death. CEP-1347 has the ability not only to inhibit cell death but also to maintain the trophic status of neurons in culture. The possible importance of the JNK pathway in neurodegenerative diseases such as Alzheimer's and Parkinson's diseases provides a rationale for the use of CEP-1347 for the treatment of these diseases. CEP-1347 has the potential of not only retarding disease progression but also reversing the severity of symptoms by improving the function of surviving neurons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744254     DOI: 10.1146/annurev.pharmtox.44.101802.121840

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  49 in total

Review 1.  Pharmacological manipulation of cell death: clinical applications in sight?

Authors:  Douglas R Green; Guido Kroemer
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 2.  MAP kinase pathways: the first twenty years.

Authors:  Joseph Avruch
Journal:  Biochim Biophys Acta       Date:  2006-11-15

3.  (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Authors:  C-Y Chen; Y-H Weng; K-Y Chien; K-J Lin; T-H Yeh; Y-P Cheng; C-S Lu; H-L Wang
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

4.  Ablation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure.

Authors:  Oksana Polesskaya; Lisa L Cunningham; Shimon P Francis; Anne E Luebke; Xiaoxia Zhu; David Collins; Olga N Vasilyeva; Julie Sahler; Emily A Desmet; Harris A Gelbard; Sanjay B Maggirwar; Joseph P Walton; Robert D Frisina; Stephen Dewhurst
Journal:  Hear Res       Date:  2010-10-27       Impact factor: 3.208

Review 5.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

6.  LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins.

Authors:  C H Hsu; D Chan; B Wolozin
Journal:  Neurodegener Dis       Date:  2010-02-18       Impact factor: 2.977

Review 7.  Programmed cell death and new discoveries in the genetics of parkinsonism.

Authors:  Robert E Burke
Journal:  J Neurochem       Date:  2007-12-10       Impact factor: 5.372

8.  Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3.

Authors:  Rajakishore Mishra; Manoj K Barthwal; Gautam Sondarva; Basabi Rana; Lucas Wong; Malay Chatterjee; James R Woodgett; Ajay Rana
Journal:  J Biol Chem       Date:  2007-08-21       Impact factor: 5.157

9.  Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Authors:  Val S Goodfellow; Colin J Loweth; Satheesh B Ravula; Torsten Wiemann; Thong Nguyen; Yang Xu; Daniel E Todd; David Sheppard; Scott Pollack; Oksana Polesskaya; Daniel F Marker; Stephen Dewhurst; Harris A Gelbard
Journal:  J Med Chem       Date:  2013-10-03       Impact factor: 7.446

10.  Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.

Authors:  Delphine Charvin; Peter Vanhoutte; Christiane Pagès; Emilliana Borrelli; Emiliana Borelli; Jocelyne Caboche
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.